Daniel R. Passeri Purchases 30,000 Shares of Cue Biopharma, Inc. (NASDAQ:CUE) Stock

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Daniel R. Passeri bought 30,000 shares of the business’s stock in a transaction on Monday, December 16th. The shares were purchased at an average cost of $1.03 per share, with a total value of $30,900.00. Following the transaction, the chief executive officer now owns 164,578 shares in the company, valued at approximately $169,515.34. The trade was a 22.29 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Cue Biopharma Stock Down 4.7 %

NASDAQ CUE opened at $1.02 on Friday. The stock’s 50 day moving average is $1.31 and its two-hundred day moving average is $1.05. Cue Biopharma, Inc. has a 1-year low of $0.45 and a 1-year high of $3.20. The company has a market capitalization of $64.62 million, a price-to-earnings ratio of -1.13 and a beta of 1.66. The company has a current ratio of 2.22, a quick ratio of 2.22 and a debt-to-equity ratio of 0.05.

Institutional Investors Weigh In On Cue Biopharma

A number of hedge funds have recently added to or reduced their stakes in the stock. Sigma Planning Corp boosted its stake in Cue Biopharma by 50.9% in the third quarter. Sigma Planning Corp now owns 401,325 shares of the company’s stock valued at $304,000 after acquiring an additional 135,295 shares during the last quarter. Good Life Advisors LLC increased its position in shares of Cue Biopharma by 23.1% during the 3rd quarter. Good Life Advisors LLC now owns 400,000 shares of the company’s stock worth $303,000 after purchasing an additional 75,000 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Cue Biopharma in the 2nd quarter valued at about $66,000. Geode Capital Management LLC raised its position in shares of Cue Biopharma by 3.3% in the third quarter. Geode Capital Management LLC now owns 508,827 shares of the company’s stock valued at $385,000 after purchasing an additional 16,371 shares during the period. Finally, GSA Capital Partners LLP boosted its stake in Cue Biopharma by 5.1% in the 3rd quarter. GSA Capital Partners LLP now owns 291,663 shares of the company’s stock valued at $221,000 after purchasing an additional 14,104 shares during the period. Institutional investors own 35.04% of the company’s stock.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.